reports
Valneva to Meet with Investors during the J.P. Morgan Healthcare Confe...
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference Saint Herblain (France), January 6, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which is expected to generate €160 -...
VALNEVA Declaration of shares and voting rights: December 31, 2024
VALNEVA Declaration of shares and voting rights: December 31, 2024 VALNEVA Declaration of shares and voting rights December 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...
- Bruno Bulic
Valneva pushing Ixchiq in Asia
Valneva announced an exclusive license agreement with India-based Serum Institute of India (SII), for the supply of the Chikungunya vaccine Ixchiq in Asia, a partnering falling under the scope of the Coalition for Epidemic Preparedness Innovations (CEPI) for low-and-middle-income countries (LMICs)
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccin...
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India Saint-Herblain (France), Pune, (India), December 19, 2024 – (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the fram...
Valneva accroît l’accessibilité de son vaccin contre le chikungunya en...
Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India Saint-Herblain (France), Pune, (Inde), le 19 décembre 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, et le Serum Institute of India (SII), plus grand fabricant de vaccins au monde en nombre de doses, ont annoncé la signature d’un accord de licence exclusif pour le vaccin à dose unique de Valneva contre le chikungunya, permettant la fourniture du vaccin en Asie. Cette collaboration destinée à accroître l’accessibilité du...
VALNEVA - Declaration of shares and voting rights: November 30, 2024
VALNEVA - Declaration of shares and voting rights: November 30, 2024 VALNEVA Declaration of shares and voting rights November 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change ...
Valneva Reports Positive Three-Year Antibody Persistence Data for its ...
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectat...
Valneva annonce des données positives sur la persistance des anticorps...
Valneva annonce des données positives sur la persistance des anticorps à trois ans pour son vaccin à dose unique contre le chikungunya, IXCHIQ® Les niveaux d’anticorps demeurent élevés avec un taux de séro-réponse de 96 %, en ligne avec les données obtenues à deux ansLa persistance à long terme des anticorps est comparable chez les adultes âgés (plus de 65 ans) et les jeunes adultes Saint-Herblain (France), le 3 décembre 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui des données positives sur la persistance des anticorps trois a...
Valneva Submits Label Extension Application for its Chikungunya Vaccin...
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-year anti...
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Cha...
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacc...
Valneva fera des présentations et rencontrera les investisseurs lors d...
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe Saint-Herblain (France), le 12 novembre 2024 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Lors de ces présentations, Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux é...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and Eur...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Saint-Herblain (France), November 12, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cataly...
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Damien Choplain
- Martial Descoutures
Valneva : Ixchiq struggling – full-year guidance adjusted
>Top line in line and EBITDA higher than expected – Disappointment on Ixchiq - Valneva reported 9M 2024 results in line with expectation for sales (+0%) and above the css for adjusted EBITDA (+13%). Product sales rose 6% to € 110.4m (+2% vs css) driven by Ixiaro (+31%, +4% vs css) and Dukoral (+6%, +10% vs css) boosted in Q3 (+85%) by the pick-up in marketing outlays. The disappointment in this release came from the performance of Ixchiq which is struggling to get goi...
- Damien Choplain
- Martial Descoutures
Valneva : Ixchiq peine à décoller – guidance FY ajustée
>Topline en ligne et EBITDA au-dessus des attentes – Déception sur Ixchiq - Valneva publie des résultats 9M 2024 en ligne au niveau du CA (+0%) et au-dessus du css au niveau de l’EBITDA ajusté (+13%). Les ventes de produits sont en hausse de 6% à 110.4 M€ (+2% vs Css) tirées par Ixiaro (+31%, +4% vs css) et Dukoral (+6%, +10% vs css) bénéficiant au T3 (+85%) de la reprise des investissements en marketing. La déception de cette publication provient de la performance d’...
- Bruno Bulic
- Oscar Haffen Lamm
Valneva: a mixed-bag of 9M24 results
Valneva has reported a mixed-bag of 9M results with sales at EUR112.5m (cons. EUR110.4m) +12% yoy (excluding Covid-19 revenue in 2023), operating profit of EUR34.2m (cons. EUR29m), translating into an underlying est. EUR61m operating loss excluding the EUR95m profit from the sale of the Priority Vo
Valneva Reports Nine-Month 2024 Financial Results and Provides Corpora...
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D b...
Valneva publie ses résultats financiers pour les neuf premiers mois de...
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités Principaux éléments financiers pour les neuf premiers mois de l’exercice 2024 Chiffre d’affaires total de 116,6 millions d’euros comprenant des ventes de produits de 112,5 millions d’eurosBénéfice net de 24,7 millions d’euros incluant le produit de la vente du bon de revue prioritaire (PRV)1 Bénéfice opérationnel de 34,2 millions d’euros contre une perte opérationnelle de (57,2) millions d’euros sur les neuf premiers mois de l’exercice 2023 Trésorerie de 156,3 millions ...
VALNEVA - Declaration of shares and voting rights: October 31, 2024
VALNEVA - Declaration of shares and voting rights: October 31, 2024 VALNEVA Declaration of shares and voting rights October 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.